Clinical trials: Tumor Pancreas
Cholangiocarcinoma, Hepatocellular Carcinoma
In Vitro Models of Liver and Pancreatic Cancer
The primary objective is to develop an in vitro model of cancer for laboratory study using liver, biliary and pancreatic cancer tissue.
- Conditions
- Cholangiocarcinoma, Hepatocellular Carcinoma, Pancreatic Neoplasm
- Trial name
- NCT02436564
- Testing
- Organoid in vitro culture
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Biliary Tract Neoplasms, Pancreatic Neoplasms
The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer
Evaluate the efficacy and safety of Trilaciclib for myeloprotection prior to chemotherapy in advanced cholangiocarcinoma or pancreatic cancer.
- Trial name
- NCT07160283
- Testing
- Bile duct cancer cohort, Pancreatic cancer cohort
- Volunteers
- 96 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Carcinoma, Metastatic Pancreatic Adenocarcinoma
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
- Trial name
- NCT03611556
- Testing
- Oleclumab, Durvalumab, Gemcitabine
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 213 people
- Sponsor
- MedImmune LLC
Neuroendocrine Carcinoma of Lung, Neuroendocrine Carcinoma of Thymus
CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 > 20%).
- Trial name
- LINEAR (NCT07429851)
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- European Institute of Oncology
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
This phase Ib/II trial studies the side effects and best dose of bispecific antibody armed activated T-cells when given together with aldesleukin and sargramostim and to see how well they work in treating patients with pancreatic…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT02620865
- Testing
- Aldesleukin, Antibody Therapy, Fluorouracil
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Pancreatic Cancer
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic…
- Trial name
- NCT01688336
- Testing
- FOLFIRINOX
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced Pancreatic Cancer
A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer
The study is being conducted to: a) evaluate the tolerability and safety of the co-administration of Fluzoparib and mFOLFIRINOX followed by Fluzoparib Maintenance Monotherapy in patients with advanced pancreatic cancer, and…
- Trial name
- NCT04228601
- Testing
- Fluzoparib, mFOLFIRINOX
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Cancer
Study of Sirolimus in Patients With Advanced Pancreatic Cancer
Pancreatic cancer is a highly malignant tumor of the digestive system.In China, the annual mortality/morbidity of pancreatic cancer is as high as 0.88:1, and the morbidity and mortality are still on the rise.
- Trial name
- NCT03662412
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
IPMN, Pancreatic
Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium
Although intraductal papillary mucinous neoplasms (IPMNs) represent potential precursors of pancreatic cancer, IPMNs with invasive cancer are rare.
- Trial name
- INCITE (NCT06694792)
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Adenocarcinoma Metastatic
Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy
The objectives of the study are to evaluate the efficacy (primary endpoint: overall survival), safety (secondary endpoint) and the medico-economic impact (secondary endpoint) of nanoliposomal irinotecan combined with…
- Trial name
- NALIRI-PANC (NCT06006728)
- Where
- France
- Volunteers
- 58 people
- Sponsor
- University Hospital, Bordeaux
PDAC - Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS
The goal of this intermediate-size expanded access treatment program is to treat a subset of patients with advanced solid cancers, specifically pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), that express…
- Trial name
- NCT07614048
- Testing
- Cyclophosphamide, Fludarabine, Cell infusion
- Sponsor
- Providence Health & Services
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as possible (debulking surgery) works in treating patients with grade 1…
- Conditions
- Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT06016855
- Testing
- Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Pancreas Cancer, Pancreas Cyst
ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer
Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated in subjects with pancreas cancer. Researchers are looking to use this test to compare subjects with pancreas cancer and subjects…
- Trial name
- NCT04064034
- Testing
- Lateral Flow Assay (LFA)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with solid tumors
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT07261631
- Testing
- 68Ga-NNS309, 177Lu-DFC413
- Where
- 9 sites in United States, Canada and 5 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Neoplasms
Expression of Inflammatory Proteins in Pancreatic Cancer
The purpose of this trial is to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue.
- Trial name
- NCT00551057
- Testing
- Expression type
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- University of Zurich
Lung Adenocarcinoma, Breast Adenocarcinoma
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
The p63 gene is a recently discovered member of the p53 family located at chromosome 3q27Many studies have reported that overexpression of p63 can mimic p53 activities by binding DNA, activating transcription, and inducing…
- Conditions
- Lung Adenocarcinoma, Breast Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT01942629
- Testing
- their will be no intervention in any of the groups, the study is retrospective
- Volunteers
- 300 people
- Sponsor
- Rambam Health Care Campus
Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.
- Conditions
- Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT07021066
- Testing
- BL-M05D1
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- SystImmune Inc.
Pancreatic Cancer
Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer
This is a prospective, multi-center, multi-cohort exploratory study. Cohort 1 enrolls 39 patients with unresectable locally advanced or metastatic pancreatic cancer, who will receive first-line treatment with cisplatin plus…
- Trial name
- NCT07828756
- Testing
- Cisplatin, Albumin-bound Paclitaxel (Ⅱ), Capecitabine
- Where
- China
- Volunteers
- 147 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced and Selected Solid Tumors
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
This is an open label, dose finding, phase Ib clinical trial to determine the maximum tolerated dose (MTD) and /or recommended phase II dose (RP2D) and schedule for the PI3K (Phosphatidylinositol 3-Kinase) inhibitor BKM120 given…
- Trial name
- NCT01155453
- Testing
- BKM120, GSK1120212
- Where
- 7 sites in United States, Belgium and 3 more
- Volunteers
- 113 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)
In this prospective study, new diagnostic tools will be explored for patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (BR or LAPDA) who undergo neoadjuvant chemotherapy with FOLFIRINOX.
- Trial name
- PeRFormanCe (NCT05298722)
- Testing
- Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.
- Where
- 8 sites in Belgium, Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.